Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
May 01, 2024 (filed on May 03, 2024)Insider Name:McCourt MarionOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$889.41
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17Price:$898.51
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$897.68
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3Price:$896.59
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$895.38
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5Price:$893.16
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$892.50
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7Price:$891.52
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1Price:$913.21
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1Price:$912.29
Filings by filing date
-
May 01, 2024 (filed on May 03, 2024)Insider Name:McCourt MarionOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-250Price:$889.41
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17Price:$898.51
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$897.68
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3Price:$896.59
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2Price:$895.38
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5Price:$893.16
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9Price:$892.50
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-7Price:$891.52
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1Price:$913.21
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Ryan Arthur FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1Price:$912.29
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 777 Old Saw Mill River Road TARRYTOWN NY 10591 |
Tel: | N/A |
Website: | https://www.regeneron.com |
IR: | See website |
Key People | ||
Leonard S. Schleifer Co-Chairman of the Board, President, Chief Executive Officer, Founder | George D. Yancopoulos Co-Chairman of the Board, President, Chief Scientific Officer | Christopher R. Fenimore Chief Financial Officer, Senior Vice President - Finance |
Joseph J. LaRosa Executive Vice President, General Counsel, Secretary | Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply | Marion E. McCourt Executive Vice President - Commercial |
Andrew J. Murphy Executive Vice President - Research | Neil Stahl Executive Vice President - Research and Development | Jason Pitofsky Vice President, Controller |
Business Overview |
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others. |
Financial Overview |
For the three months ended 31 March 2024, Regeneron Pharmaceuticals Inc revenues decreased 1% to $3.15B. Net income decreased 12% to $722M. Revenues reflect EYLEA segment decrease of 16% to $1.2B, Roche segment decrease of 100% to $500K. Net income also reflects Research and development increase of 26% to $706.5M (expense), selling increase of 15% to $602.8M (expense). |
Employees: | 13,450 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $97,631M as of Mar 31, 2024 |
Annual revenue (TTM): | $13,100M as of Mar 31, 2024 |
EBITDA (TTM): | $4,425M as of Mar 31, 2024 |
Net annual income (TTM): | $3,858M as of Mar 31, 2024 |
Free cash flow (TTM): | $3,930M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 110,185,503 as of Apr 16, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |